In vitro podocyte experiments also showed the same results after treatment with AS-IV in the context of HG, demonstrating that AS-IV can alleviate DKD progression by regulating the SIRT6/HIF-1α/NLRP3 axis to inhibit podocyte pyroptosis [62]. Here, SIRT6 is linked to diabetic kidney disease.